Differentiation Therapy of Cancer: Laboratory and Clinical Investigations¹

The meeting was organized and supported by Ares Serono Symposia (Italy). Contributions were also received from NIH Grant 1R13CA57162-01 (United States), Amgen (United Kingdom), Bristol-Myers Co., Ltd. (Japan), Chugai Pharmaceutical Co., Ltd. (Japan), Eizai Co., Ltd. (Japan), Farmitalia Carlo Erba Co., Ltd. (Italy), Hoffmann-La Roche (United States), ICI Pharmaceuticals (United Kingdom), Kirin Brewery Co., Ltd. (Japan), Lilly Industries, Ltd. (United Kingdom), Meiji Pharmaceutical Co., Ltd. (Japan), Nippon Roche (Japan), Otzuka Pharmaceuticals Co., Ltd. (Japan), Pfizer, Inc. (United States), The Samuel Waxman Cancer Research Foundation (United States), Sandoz Pharma, Ltd. (Switzerland), Schering-Plough (United States), Taisho Pharmaceutical Co., Ltd. (Japan), Takeda Chemical Industries, Ltd. (Japan), Wellcome SPA (Italy), Wyeth-Ayerst (United States), and Yamanouchi Pharmaceutical Co., Ltd. (Japan). This report is a summary of the Fifth International Conference on Differentiation Therapy Ares Serono Symposium which was cochaired by S. Waxman (New York), G.B. Rossi (Rome), and M. Hozumi (Saitama, Japan) and held in Vilasimius, Sardinia, Italy, September 2–5, 1992. The abstracts of the Scientific Sessions of this conference were published previously (52).